Volume 16 Supplement 1
Prognostic value of CMR in suspected CHD: 3 year follow-up of the CE-MARC study
© Greenwood et al.; licensee BioMed Central Ltd. 2014
Published: 16 January 2014
There are limited prospective, prognostic data for cardiovascular magnetic resonance (CMR) in the same patients with suspected coronary heart disease (CHD). CE-MARC established the diagnostic performance of CMR (and SPECT), with a predefined objective to determine both modalities' ability to predict major adverse cardiovascular events (MACE).
All CE-MARC patients underwent annual follow-up for 3 years to assess the occurrence of MACE (cardiovascular death, acute coronary syndrome, unscheduled revascularization or hospital admission for any cardiovascular cause). Time to MACE was assessed by univariate (log-rank test) and multivariate (Cox proportional hazards regression) analysis after adjustment for major cardiovascular risk factors. Net reclassification improvement (NRI) and discrimination (IDI) of the risk of MACE with CMR, incremental to standard clinical risk factors was calculated.
Three-year follow-up of the CE-MARC trial population demonstrates that abnormal CMR findings are independent predictors of MACE, and can reclassify patient risk beyond the standard major cardiovascular risk factors. This further supports the role of CMR for the assessment and management of patients with suspected CHD.
British Heart Foundation (RG/05/004).
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.